Correlation between Mortality of COVID-19 Patients with Hypertension and Thorax Radiography Treated in the Intensive Care Unit of Dr. Moewardi Hospital
Abstract
Background: Coronavirus 2019 or COVID-19, caused by the new SARS-CoV2 virus, has become a pandemic and attacked more than 200 countries, including Indonesia. The most comorbid disease in COVID-19 patients was hypertension. Chest radiography can predict prognosis and mortality in COVID-19 cases and one of the methods that can be used for chest radiographic assessment is the Brixia Score, specifically designed for COVID-19 patients to measure and analyze the severity of lung abnormalities in patients with COVID-19. This study aimed to find the correlation between the mortality of COVID-19 patients with hypertension and chest radiography using the Brixia Score treated in the intensive care unit (ICU) of Dr. Moewardi Hospital.
Subjects and Method: This study used an analytic observational study with a cross-sectional approach. The subjects were 84 COVID-19 patients with hypertension who met the exclusion and inclusion criteria. The independent variable is chest radiography and dependent variable is mortality. Sampling was collected by purposive sampling and the data obtained were analyzed using the contingency coefficient test.
Results: There was a significant correlation between the mortality of COVID-19 patients with hypertension and chest radiography as assessed using the Brixia Score (p<0.001). The youngest patient was 20 years old and the oldest was 87 years old.
Conclusion: There was a correlation between the mortality of COVID-19 patients with hypertension and chest radiography treated in the ICU RSUD Dr. Moewardi, Surakarta.
Keywords: COVID-19, mortality, hypertension, chest radiography, Brixia Score, intensive care unit
Correspondence: Widiastuti Soewondo. Faculty of Medicine Universitas Sebelas Maret Surakarta. Jl. Ir. Sutami 36A, Surakarta 57126, Indonesia. Email: Widiastuti.sprad56@staff.uns.ac.id. Mobile: 082134368592.
Indonesian Journal of Medicine (2022), 07(03): 269-277
https://doi.org/10.26911/theijmed.2022.07.03.03
References
Balbi M, Caroli A, Corsi A, Milanese G, Surace A, Marco FD, Novelli L, et al. (2021). Chest Xray for predicting mortality and the need for ventilatory support in COVID19 patients presenting to the emergency department. Eur. Radiol. 31: 1999–2012. doi: 10.1007/s00330020072701.
Baud D, Qi X, NielsenSaines K, Musso D, Pomar L, Favre G (2020). Real estimates of mortality following COVID19 infection. Lancet Infect. Dis. 20(7): 773. doi: 10.1016/S14733099(20)30195X.
Borghesi A, Zigliani A, Golemi S, Carapella N, Maculotti P, Farina D, Maroldi R (2020). Chest Xray severity index as a predictor of inhospital mortality in coronavirus disease 2019: A study of 302 patients from Italy. IJID. 96: 291–293. doi: 10.1016/j.ijid.2020.05.021.
Borghesi A, Zigliani A, Masciullo R, Golemi S, Maculotti P, Farina D, Maroldi R (2020). Radiographic severity index in COVID19 pneumonia: relationship to age and sex in 783 Italian patients. Radiol Med. 125: 461–464. doi: 10.1007/s11547020012021.
Du Y, Zhou N, Zha W, Lv Y (2021). Hypertension is a clinically important risk factor for critical illness and mortality in COVID19: A metaanalysis. NMCD. 31(3): 745–755. doi: 10.1016/J.NUMECD.2020.12.009.
Hedibah S, Tharwat N, Elmokadem A (2021). Is chest Xray severity scoring for COVID19 pneumonia reliable? Pol. J. Radiol. 86: 432–439. doi: 10.5114/pjr.2021.108172.
Hikmawati I, Setiyabudi R (2021) Epidemiology of COVID19 in Indonesia: common source and propagated source as a cause for outbreaks. J Infect Dev Ctries. 15: 646652. doi: 10.3855/jidc.14240.
Hoang S, Nguyen K, Huynh TM, Huynh K, Nguyen P, Tran H (2022). Chest Xray Severity Score as a Putative Predictor of Clinical Outcome in Hospitalized Patients: An Experience From a Vietnamese COVID19 Field Hospital. Cureus. doi: 10.7759/cureus.23323.
Kang SJ, Jung SI (2020). AgeRelated Morbidity and Mortality among Patients with COVID19. Infect Chemother. 52(2): 154164. doi: 10.3947/ic.2020.52.2.154.
Kario K, Morisawa Y, Sukonthasarn A, Turana Y, Chia YC, Park S, Wang TD, et al. (2020). Hypertension Cardiovascular Outcome Prevention, Evidence in Asia (HOPE Asia) Network. COVID19 and hypertensionevidence and practical management: Guidance from the HOPE Asia Network. J Clin Hypertens (Greenwich). 22(7):11091119. doi: 10.1111/jch.13917.
Maroldi R, Rondi P, Agazzi GM, Ravanelli M, Borghesi A, Farina D (2021). Which role for chest xray score in predicting the outcome in COVID19 pneumonia?. Eur Radiol. 31: 4016-4022. doi: 10.1007/s00330020075042
Oster JR, Materson BJ, PerezStable E (2022). Antihypertensive Medications. South. Med. J. 77(5): 621–630. doi: 10.1097/0000761119840500000020.
Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, Rosser EC, et al. (2020). Male sex identified by global COVID19 metaanalysis as a risk factor for death and ITU admission. Nat Commun. 11(1): 6317. doi: 10.1038/s41467020197416.
RezelPotts E, Douiri A, Chowienczyk PJ, Gulliford MC (2021). Antihypertensive medications and COVID19 diagnosis and mortality: Populationbased casecontrol analysis in the United Kingdom. Br J Clin Pharmacol. 87. doi: 10.1111/bcp.14873.
WHO. (2021). COVID19 weekly epidemiological update. World Health Organization. 58: 1–23. Available at https://www.who.int/publications/m/item/covid19weeklyepidemiologicalupdate.
